Radar›Companies›Pharmaceutical Preparations Stocks in USA: Revenue Cohort 10
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Revenue Cohort 10

A five-company pharmaceutical preparations cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderKeros Therapeutics · 51
Strongest available pathAnaptysBio · +235.6%
Widest latest marginKeros Therapeutics · 35.7%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1KROS · Nasdaq

Keros Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2016Lexington, Massachusetts$218.7M market cap
View full Companies Radar profile
51Moderate
Snapshot price$11.03as of page date
Monthly-close return-66.6%five-year window
FY2025 revenue$0.24BKeros Therapeutics, Inc.
Net margin35.7%FY2025
P/E snapshot-1.7xone ratio, not a verdict
Prism attention9.7%share across these five
Filing track recordRevenue, USD billions
+1114.2%
$0$0.1B$0.2B$0.2BFY2021: $0.020BFY2023: $0.000BFY2024: $0.004BFY2025: $0.244B2021202320242025
FY2021–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 129.8%
52-week position10% through range
$9.69$22.55
News mentions458
Community mentions5partial coverage
U.S.-scope patents174
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal87/100
Management stability70/100
Market position3/100
Capital-event signal64/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2PBYI · Nasdaq

Puma Biotechnology

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Los Angeles, California$467.7M market cap
View full Companies Radar profile
46Cautious
Snapshot price$9.06as of page date
Monthly-close return+22.1%five-year window
FY2025 revenue$0.23BPUMA BIOTECHNOLOGY, INC.
Net margin13.6%FY2025
P/E snapshot17.8xone ratio, not a verdict
Prism attention20.4%share across these five
Filing track recordRevenue, USD billions
-9.8%
$0$0.1B$0.2B$0.3BFY2021: $0.253BFY2022: $0.228BFY2023: $0.236BFY2024: $0.230BFY2025: $0.228B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -2.5%
52-week position91% through range
$4.30$9.51
News mentions964
Community mentions11partial coverage
U.S.-scope patents0
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal53/100
Management stability90/100
Market position3/100
Capital-event signal59/100
Innovation pulse12/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3AKBA · Nasdaq

Akebia Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2007Cincinnati, Ohio$243.5M market cap
View full Companies Radar profile
44Cautious
Snapshot price$0.88as of page date
Monthly-close return-68.0%five-year window
FY2025 revenue$0.24BAkebia Therapeutics, Inc.
Net margin-2.3%FY2025
P/E snapshot-2.7xone ratio, not a verdict
Prism attention24.5%share across these five
Filing track recordRevenue, USD billions
+10.6%
$0$0.1B$0.2B$0.3BFY2021: $0.214BFY2022: $0.293BFY2023: $0.195BFY2024: $0.160BFY2025: $0.236B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.5%
52-week position3% through range
$0.81$3.22
News mentions1.2K
Community mentions18partial coverage
U.S.-scope patents539
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal45/100
Management stability90/100
Market position9/100
Capital-event signal44/100
Innovation pulse27/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 9 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4IDYA · Nasdaq

Ideaya Biosciences

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2015San Francisco, California$3.87B market cap
View full Companies Radar profile
43Cautious
Snapshot price$40.11as of page date
Monthly-close return+77.7%five-year window
FY2025 revenue$0.22BIDEAYA Biosciences, Inc.
Net margin-52.0%FY2025
P/E snapshot-9.8xone ratio, not a verdict
Prism attention24.2%share across these five
Filing track recordRevenue, USD billions
+682.8%
$0$0.1B$0.1B$0.2BFY2021: $0.028BFY2022: $0.051BFY2023: $0.023BFY2024: $0.007BFY2025: $0.219B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 67.3%
52-week position87% through range
$23.23$42.68
News mentions1.1K
Community mentions7partial coverage
U.S.-scope patents311
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal44/100
Management stability90/100
Market position10/100
Capital-event signal63/100
Innovation pulse8/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 4 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5ANAB · Nasdaq

AnaptysBio

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2005San Diego, California$1.67B market cap
View full Companies Radar profile
31Cautious
Snapshot price$56.28as of page date
Monthly-close return+235.6%five-year window
FY2025 revenue$0.23BANAPTYSBIO, INC
Net margin-5.6%FY2025
P/E snapshot12.9xone ratio, not a verdict
Prism attention21.2%share across these five
Filing track recordRevenue, USD billions
+271.4%
$0$0.1B$0.2B$0.2BFY2021: $0.063BFY2022: $0.010BFY2023: $0.017BFY2024: $0.091BFY2025: $0.235B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 38.8%
52-week position74% through range
$11.40$72.36
News mentions1.0K
Community mentions11partial coverage
U.S.-scope patents326
Prism Insights

What sits behind the readiness signal

Observed risk 7/100higher means more observed risk
Earnings signal34/100
Management stability90/100
Market position0/100
Capital-event signal39/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 2 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

AnaptysBio
+235.6%
Ideaya Biosciences
+77.7%
Puma Biotechnology
+22.1%
Keros Therapeutics
-66.6%
Akebia Therapeutics
-68.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Keros Therapeutics
$0.24B
Akebia Therapeutics
$0.24B
AnaptysBio
$0.23B
Puma Biotechnology
$0.23B
Ideaya Biosciences
$0.22B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Keros Therapeutics
35.7%
Puma Biotechnology
13.6%
Akebia Therapeutics
-2.3%
AnaptysBio
-5.6%
Ideaya Biosciences
-52.0%

Prism news attention

Normalized share across these five names; attention is not quality.

Akebia Therapeutics
24.5%
Ideaya Biosciences
24.2%
AnaptysBio
21.2%
Puma Biotechnology
20.4%
Keros Therapeutics
9.7%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Akebia Therapeutics leads the conversation

It holds 24.5% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.24B.

Price path

AnaptysBio leads the available price paths

Its monthly-close return is +235.6% for the five-year window. At the other end, Akebia Therapeutics is -68.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Keros Therapeutics has the widest latest margin

Its FY2025 net margin is 35.7%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Ideaya Biosciences shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -9.8x while its five-year window price return is +77.7%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · PBYI

Puma Biotechnology

964available Prism news records

Prism top themes

Price action & investor response
36
Earnings & financial performance
30
Leadership & governance
14
Capital allocation & transactions
13
Legal, arbitration & regulatory
9

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-16.0%89 latest 12m vs 106 prior 12m
2024-01: 9 mentions2024-02: 15 mentions2024-03: 6 mentions2024-04: 8 mentions2024-05: 17 mentions2024-06: 6 mentions2024-07: 7 mentions2024-08: 2 mentions2024-09: 4 mentions2024-10: 3 mentions2024-11: 15 mentions2024-12: 10 mentions2025-01: 7 mentions2025-02: 25 mentions2025-03: 6 mentions2025-04: 10 mentions2025-05: 12 mentions2025-06: 5 mentions2025-07: 0 mentions2025-08: 10 mentions2025-09: 13 mentions2025-10: 3 mentions2025-11: 8 mentions2025-12: 4 mentions2026-01: 7 mentions2026-02: 17 mentions2026-03: 5 mentions2026-04: 12 mentions2026-05: 9 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

90.2% positive-3.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

business award 17industry award 17stock performance 13earnings report 12cancer biomarkers 12company valuation 11stock price 11neoadjuvant therapy breast cancer 10

Keyword tag occurrences in available Prism news records.

Coverage: 2011-05-24–2026-06-01 · trend and themes shown through 2026-06
Areas of research · AKBA

Akebia Therapeutics

1,152available Prism news records

Prism top themes

Price action & investor response
51
Capital allocation & transactions
39
Earnings & financial performance
29
Leadership & governance
28
Legal, arbitration & regulatory
16

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+27.7%166 latest 12m vs 130 prior 12m
2024-01: 17 mentions2024-02: 5 mentions2024-03: 27 mentions2024-04: 3 mentions2024-05: 13 mentions2024-06: 13 mentions2024-07: 16 mentions2024-08: 6 mentions2024-09: 2 mentions2024-10: 10 mentions2024-11: 10 mentions2024-12: 1 mentions2025-01: 11 mentions2025-02: 22 mentions2025-03: 20 mentions2025-04: 13 mentions2025-05: 8 mentions2025-06: 11 mentions2025-07: 7 mentions2025-08: 8 mentions2025-09: 7 mentions2025-10: 18 mentions2025-11: 12 mentions2025-12: 11 mentions2026-01: 17 mentions2026-02: 21 mentions2026-03: 4 mentions2026-04: 43 mentions2026-05: 16 mentions2026-06: 2 mentions2024-012026-06

Machine-classified coverage tone

93.5% positive-4.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 19company valuation 16startup valuation 13investor conference 7stock performance 4share price 4market reaction 4angiogenesis inhibitors 3

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-05–2026-06-07 · trend and themes shown through 2026-06
Areas of research · IDYA

Ideaya Biosciences

1,144available Prism news records

Prism top themes

Price action & investor response
116
Legal, arbitration & regulatory
96
Earnings & financial performance
27
Capital allocation & transactions
20
Leadership & governance
17

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+14.1%316 latest 12m vs 277 prior 12m
2024-01: 7 mentions2024-02: 10 mentions2024-03: 14 mentions2024-04: 16 mentions2024-05: 26 mentions2024-06: 17 mentions2024-07: 32 mentions2024-08: 25 mentions2024-09: 19 mentions2024-10: 16 mentions2024-11: 24 mentions2024-12: 16 mentions2025-01: 18 mentions2025-02: 53 mentions2025-03: 28 mentions2025-04: 30 mentions2025-05: 10 mentions2025-06: 6 mentions2025-07: 8 mentions2025-08: 11 mentions2025-09: 67 mentions2025-10: 22 mentions2025-11: 15 mentions2025-12: 37 mentions2026-01: 28 mentions2026-02: 32 mentions2026-03: 26 mentions2026-04: 40 mentions2026-05: 24 mentions2026-06: 6 mentions2024-012026-06

Machine-classified coverage tone

86.0% positive-6.7 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

angiogenesis inhibitors 44cancer biomarkers 25adc therapeutics 21stock price 19stock performance 18uv index melanoma 17photoprotection melanoma 15uv radiation melanoma 15

Keyword tag occurrences in available Prism news records.

Coverage: 2016-05-03–2026-06-13 · trend and themes shown through 2026-06
Areas of research · ANAB

AnaptysBio

1,001available Prism news records

Prism top themes

Price action & investor response
103
Legal, arbitration & regulatory
53
Leadership & governance
32
Earnings & financial performance
29
Capital allocation & transactions
22

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+7.2%239 latest 12m vs 223 prior 12m
2024-01: 6 mentions2024-02: 8 mentions2024-03: 10 mentions2024-04: 6 mentions2024-05: 11 mentions2024-06: 10 mentions2024-07: 7 mentions2024-08: 28 mentions2024-09: 3 mentions2024-10: 10 mentions2024-11: 17 mentions2024-12: 17 mentions2025-01: 6 mentions2025-02: 79 mentions2025-03: 19 mentions2025-04: 1 mentions2025-05: 22 mentions2025-06: 14 mentions2025-07: 3 mentions2025-08: 5 mentions2025-09: 12 mentions2025-10: 8 mentions2025-11: 33 mentions2025-12: 15 mentions2026-01: 25 mentions2026-02: 13 mentions2026-03: 30 mentions2026-04: 54 mentions2026-05: 40 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

84.5% positive-2.6 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 32stock price 24share price 19adc therapeutics 10phase ii trial 9startup valuation 8phase iii trial 8immunotherapy 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-11–2026-06-02 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

KROS

Keros Therapeutics

through 2025-08-20
Company announcements 5Business contracts 1Earnings releases 1Listing / IPO 1M&A 1
  1. M&A

    Others, like Pliant Therapeutics and Keros Therapeutics, have faced investor pressure.

  2. Company announcements

    In a separate press release issued today, the Company announced its financial results for the second quarter ended June 30, 2025.

  3. Earnings releases

    Cantor Fitzgerald expects that the company will earn ($5.82) per share for the year.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PBYI

Puma Biotechnology

through 2026-02-04
Earnings releases 22Company announcements 4Listing / IPO 2Regulatory 1
  1. Company announcements

    Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 14,750 shares of Puma common stock to two new non-executive employees.

  2. Earnings releases

    For the third quarter of 2025, total revenue was $54.5 million, of which $51.9 million was product revenue, net and $2.6 million was royalty revenue.

  3. Listing / IPO

    Puma Biotechnology Inc. raised $138 million from a public offering of shares at $122.50 each.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AKBA

Akebia Therapeutics

through 2026-04-03
Earnings releases 17Company announcements 9Leadership changes 5Regulatory 3Business contracts 1
  1. Company announcements

    "He said a Phase 1 study has initiated in New Zealand, with Akebia expecting Phase 1 data before the end of 2026."

  2. Earnings releases

    Revenues: Total revenues increased to $62.5 million in the second quarter of 2025 compared to $43.6 million in the second quarter of 2024, driven by sales of Vafseo, which was launched in the U.S. in January 2025, and an increase in Auryxia sales.

  3. Listing / IPO

    Akebia Therapeutics Inc. priced 7.25 million shares at $9 each for gross proceeds of $65.3 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

IDYA

Ideaya Biosciences

through 2026-03-27
Company announcements 17Business contracts 4Earnings releases 3Listing / IPO 3Regulatory 2
  1. Company announcements

    the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 49,000 shares of the Company's common stock to two newly hired employees.

  2. M&A

    Last September, Servier paid Ideaya Biosciences $230 million up front for rights outside of the U.S. to darovasertib, which is in late‑stage development for a rare type of eye cancer.

  3. Business contracts

    Ideaya disclosed last Friday that GSK communicated to Ideaya its election to terminate the collaboration, option and license agreement. Pursuant to the terms of the agreement, such termination will be effective 90 days following the date of GSK’s written notice of December 4. During the ninety-day transition period, GSK will transfer the Werner Helicase and Pol Theta clinical programs to Ideaya.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ANAB

AnaptysBio

through 2026-04-27
Earnings releases 9Listing / IPO 3Lawsuits 2Business contracts 1Company announcements 1
  1. Lawsuits

    TESARO, a subsidiary of GSK plc (LSE/NYSE: GSK), has announced an update regarding its ongoing legal dispute with AnaptysBio, Inc. The Delaware Chancery Court granted AnaptysBio’s motion to dismiss TESARO’s claim for anticipatory breach.

  2. Earnings releases

    Net loss was $38.6 million and $78.0 million for the three and six months ended June 30, 2025, or a net loss per share of $1.34 and $2.62.

  3. Company announcements

    On June 3, 2025, AnaptysBio announced positive results from its Phase 2b RENOIR clinical trial for rosnilimab, a treatment targeting PD-1+ T cells in patients with moderate-to-severe rheumatoid arthritis.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 46–53. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with Keros Therapeutics and Keros Therapeutics

Keros Therapeutics has the largest displayed latest revenue at $0.24B; Keros Therapeutics has the widest displayed latest margin at 35.7%.

Open Keros Therapeutics in Companies Radar
Comparisons
Anomalies

Keros Therapeutics has the widest attention-readiness rank gap

It ranks #5 by measured news attention (9.7%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Keros Therapeutics in Companies Radar

Keros Therapeutics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +1114.2% while its available monthly-close return is -66.6%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Keros Therapeutics in Companies Radar
Explanations

Attention measures coverage volume, not quality

Akebia Therapeutics's 24.5% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Akebia Therapeutics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Keros Therapeutics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 51/100 score.

Open Keros Therapeutics in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon